In the Phase 3 CheckMate -901 trial, Opdivo with cisplatin and gemcitabine demonstrated a statistically significant improvement in overall survival and progression-free survival compared to ...

Quality of Life in the Intergroup Exemestane Study: A Randomized Trial of Exemestane Versus Continued Tamoxifen After 2 to 3 Years of Tamoxifen in Postmenopausal Women With Primary Breast Cancer To ...

Shruti Gupta, MD, MPH, and David Leaf, MD, MMSc, of the Renal Division, Department of Medicine at Brigham and Women's Hospital are the first and senior authors, respectively, of a paper published in ...

The Food and Drug Administration (FDA) has approved Opdivo (nivolumab) in combination with cisplatin and gemcitabine for the first-line treatment of adults with unresectable or metastatic bladder ...

Patients with cancer who received prophylactic intravenous (IV) magnesium before starting cisplatin had a lower risk for cisplatin-associated acute kidney injury (AKI) than those who did not receive ...

Please provide your email address to receive an email when new articles are posted on . The cisplatin shortage forced many patients with head and neck cancer to use alternative therapies. Treatment ...

The odds of cisplatin-induced acute kidney injury decreased with prophylactic administration of intravenous magnesium. Infusing prophylactic magnesium before initiating intravenous cisplatin for ...

Exploring the safety challenges, training gaps, and key protocols associated with administering chemotherapy through nontraditional routes outside dedicated oncology settings.

Cisplatin is a widely deployed chemotherapeutic agent whose clinical utility is constrained by dose-limiting toxicities, including injury to the submandibular salivary gland mediated primarily by ...

North Carolina-based Accord Healthcare is the U.S. subsidiary of Indian drugmaker Intas. (wildpixel/Getty Images) Accord Healthcare has restarted its production of the cancer drug cisplatin, which has ...